Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis
Namki Hong (Hong N), Yong-ho Lee (Lee Yh), Kenichi Tsujita (Tsujita K), Jorge A. Gonzalez (Gonzalez JA), Christopher M. Kramer (Kramer CM), Tomas Kovarnik (Kovarnik T), George N. Kouvelos (Kouvelos GN), Hiromichi Suzuki (Suzuki H), Kyungdo Han (Han K), Chan Joo Lee (Lee CJ), Sung Ha Park (Park SH), Byung-Wan Lee (Lee BW), Bong-Soo Cha (Cha BS), Eun Seok Kang (Kang ES)
Endocrinol Metab. 2018;33(2):219-227.   Published online 2018 May 4     DOI: https://doi.org/10.3803/EnM.2018.33.2.219
Citations to this article as recorded by Crossref logo
PCSK9 inhibitors and cardiovascular outcomes
Daniel Steffens, Peter Bramlage, Céline Scheeff, Mario Kasner, Adel Hassanein, Julian Friebel, Ursula Rauch-Kröhnert
Expert Opinion on Biological Therapy.2020; 20(1): 35.     CrossRef
Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
Jaehyun Bae, Namki Hong, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee
Journal of Clinical Medicine.2020; 9(3): 798.     CrossRef
Future perspectives of the pharmacological management of diabetic dyslipidemia
Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Manfredi Rizzo, Ali A. Rizvi
Expert Review of Clinical Pharmacology.2019; 12(2): 129.     CrossRef
Diabetes and Vascular Disease: Is It All About Glycemia?
Alessandra Vecchié, Fabrizio Montecucco, Federico Carbone, Franco Dallegri, Aldo Bonaventura
Current Pharmaceutical Design.2019; 25(29): 3112.     CrossRef
Triennial Report ofEndocrinology and Metabolism, 2015 to 2017
Eun-Jung Rhee, Hey Yeon Jang, Won-Young Lee
Endocrinology and Metabolism.2018; 33(2): 195.     CrossRef